US-based medical imaging company Delphinus Medical Technologies has started patient enrolment for its SoftVue Discover Breast Ultrasound Prospective Case Collection project, which will compare its SoftVue breast ultrasound device with mammography.

SoftVue is a fast, fully automated and gentle system with a 360° ring transducer that studies the entire breast in a single pass by moving from the front to the chest wall.

Unlike conventional handheld ultrasound exams that can be time-consuming, SoftVue takes approximately two to four minutes per scan, while eliminating radiation exposure and compression.

The device is designed to highlight various tissue qualities that would allow radiologists to distinguish possible cancers from normal to benign findings.

With an enrolment of 10,000 asymptomatic women with dense breast tissue at various US centres, the project will screen the participants using both digital mammography and SoftVue 3D whole-breast ultrasound exams.

"Our company’s singular focus is to transform early detection of breast cancer with our breakthrough SoftVue imaging technology."

Delphinus Medical Technologies president and CEO Mark Forchette said: “Our company’s singular focus is to transform early detection of breast cancer with our breakthrough SoftVue imaging technology."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Discover Breast Ultrasound project will enable the company to work with leading radiologists and breast cancer professionals to show the importance of its whole-breast ultrasound device that will have the capacity to detect the disease earlier, Forchette stated.

Data gathered during the project will be analysed to determine SoftVue's effectiveness in detecting cancers that could not be identified with mammography alone.

The data is expected to support the firm’s pre-marketing application (PMA) to the US Food and Drug Administration (FDA) for a supplemental screening indication of SoftVue in combination with mammography for women with dense breast tissue.